Migraine

Atogepant reduced mean monthly migraine days by more than 2 days compared to placebo in the ELEVATE trial.

Atogepant (Qulipta; AbbVie) is the first and only oral calcitonin gene-related peptide receptor antagonist to gain FDA approval for the prevention of episodic and chronic migraine.

The efficacy and tolerability of rizatriptan for acute migraine treatment has been well established.

Zavegepant is the only calcitonin gene-related peptide receptor antagonist nasal spray indicated for acute treatment of migraine in adults and can provide pain relief in 15 minutes.

Migraines are common yet misunderstood, therefore it is important that various treatment options be examined and offered to this patient population.

Zavegepant is the first calcitonin gene-related peptide receptor for migraines in development as an intranasal formulation studied in a phase 3 trial.

New research from Harvard Medical School could be a game changer for the management of headaches associated with anti-CGRP migraine therapy.

Students may be hesitant to discuss migraines, which can lead to absences, difficulties in personal life, financial burdens, and poor mental health.

Migraine could be considered a clinical marker of increased obstetric risk in pregnant women.

Patients with acute migraines should assess their condition before starting a treatment regimen.

There is a growing body of evidence that foods, substances, and additives in vitamins and supplements can be a trigger for migraine headaches.

Pharmacological options for those who experience migraines come in the form of abortive or preventative therapies.

Despite the increasing approval of neurological medications, just a small percentage of individuals are using them because of skyrocketing out-of-pocket expenses.

Prior research indicates a platelet-based connection between migraine and the patent foramen ovale.

Zavegepant could become the first intranasal drug that targets CGRP in migraine sufferers to gain FDA approval.

Atogepant is an oral calcitonin gene-related peptide receptor antagonist approved in 2021 for patients with episodic migraines.

Research into how perivascular spaces contribute to migraine could help better understand the complexities of how these headaches occur.

Investigational migraine drug produces significant effects on both freedom-from-pain and MBS-free endpoints at 3 hours post administration and at additional efficacy measurement timepoints of 4, 6, 12, 24 and 48 hours.

Updated prescribing guidelines issued in 2014 and 2016 may explain lower use of opioids by 11.7% among patients with chronic, nonsurgical pain.

A session presenter at the ASCP 2022 Annual Meeting explained how patients’ mismanagement of medications for headaches can lead to rebound headaches.

Problems such as sleep deprivation, excessive sleeping, or inability to sleep regularly may be an important factor in the transition from episodic to chronic migraines.

Case studies highlight recent developments and trends in pharmacologic treatments for migraine.

New treatments for chronic migraine have been increasing, with robust evidence for eptinezumab, erenumab, fremanezumab, galcanezumab, and onabotulinumtoxin A.

Nerivio (Theranica) remote electrical neuromodulation device found to offer similar pain relief as standard care medications as an alternative for patients with chronic migraine.

Teva Pharmaceutical Industries announced that fremanezumab can successfully reduce 2 common migraine comorbid symptoms—anxiety and depression.

Surveys show that 70% of migraine sufferers are not satisfied with their current acute treatment regimen.

Patients with chronic migraines and higher frequencies of pain experienced the lowest vitamin B12 levels compared with patients with less frequent or no headache symptoms.

Though around 42% of medical students in study experience headaches, many of these causing significant functional disability, most choose to self-manage symptoms with sleep and medication.

Analysis is based on functional magnetic resonance imaging to provide insight into the effective connectivity.

Investigators aimed to determine how individuals with and without concomitant NSP differ in characteristics and in their perception of treatment responses to analgesics.